Difference between revisions of "Clomipramine-fluoxetine"
From Psychiatrienet
| (2 intermediate revisions by the same user not shown) | |||
| Line 6: | Line 6: | ||
| start = | | start = | ||
* '''Day 6 and after''': At approximately 50-25% of the original TCA dosering start fluoxetine at 100% of the target dose. | * '''Day 6 and after''': At approximately 50-25% of the original TCA dosering start fluoxetine at 100% of the target dose. | ||
| + | * ''' After 3 weeks:''' If necessary, gradually increase dosage of fluoxetine. | ||
| info = | | info = | ||
| − | * Fluoxetine and norfluoxetine are inhibitors of CYP2D6 (strong) and CYP3A4 (moderate), which metabolize clomipramine. | + | * Safe target dose fluoxetine = 20 mg |
| + | * Fluoxetine and norfluoxetine are inhibitors of CYP2D6 (strong) and CYP3A4 (moderate), which metabolize (desmethyl)clomipramine. | ||
}} | }} | ||
Latest revision as of 12:18, 8 March 2024
| ||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
Switch medication from clomipramine to fluoxetine.[1] [2]
Stop clomipramine - Day 1: Decrease with about 25% of the original dose per 3 days.
Start fluoxetine- Day 6 and after: At approximately 50-25% of the original TCA dosering start fluoxetine at 100% of the target dose.
- After 3 weeks: If necessary, gradually increase dosage of fluoxetine.
More information- Safe target dose fluoxetine = 20 mg
- Fluoxetine and norfluoxetine are inhibitors of CYP2D6 (strong) and CYP3A4 (moderate), which metabolize (desmethyl)clomipramine.
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
